 |
 |
--------- Forwarded Message ---------- April 2007 • Clinical Trial Information for the Parkinson's Community see the website at : www.pdtrials.org New Clinical Trials Ceregene Presents Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients FDA Takes Pergolide Off US Market The 2007 Unity Walk To Be Held on April 28th Help Inform Others About Clinical Trials! Resources Do You Have Questions About Clinical Research? Order A Free Clinical Trial Informational Brochure Greetings! Thank you for signing up to receive the PDtrials Bulletin. This regular email newsletter provides you with information on Parkinson's disease clinical trials that are actively looking for participants, as well as news on Parkinson's research and treatments. PDtrials is a collaborative initiative of Parkinson's organizations and is dedicated to increasing awareness and education about Parkinson's clinical trials. Please contact us if you would like more information about this effort. New Clinical Trials Parkinson Associated Risk Study (PARS): Evaluating Potential Screening Tools for Parkinson's Disease - The PARS study is the largest long-term study in the United States of relatives of individuals with Parkinson's disease (PD). It will follow a group of 300 individuals over a two-year period to determine whether specific tests are able to predict who may be at increased risk for developing PD. The goal of the PARS study is to better understand who is at risk for PD so that it can ultimately be prevented before it starts. Learn more Study of the Effect of Long-Lasting Sequence Movements in Early-Stage and Advanced Parkinson's Disease - This study will explore sequence effect, a fatigue or tiredness commonly seen in persons with PD after they have been doing the same thing for a while. The study will use a new device called a modified peg board test to measure whether anti-parkinsonian medications (levodopa/carbidopa or dopamine) and repetitive transcranial magnetic stimulation (rTMS) of the brain can improve the symptoms of sequence effect. Learn more A Study of a New Drug, Azilect, Alone or in Combination Therapy for Parkinson's Disease - The primary goal of this study is to identify the earliest scheduled visit at which the symptomatic effect of a new drug, Azilect, as initial monotherapy, can be demonstrated. The secondary goal of this study is to characterize the effectiveness of Azilect in a usual community neurological practice by assessing investigator and participant satisfaction. This study is now only enrolling persons not currently receiving any therapy for their PD. Learn more Study of CERE-120 in People with Parkinson's Disease - The purpose of this study is to determine whether CERE-120 is a safe and effective treatment for people with PD. CERE-120 is a gene transfer agent comprised of an adeno-associated virus (AAV2) carrying the gene for neurturin (NTN). NTN is a naturally occurring protein very similar to GDNF (Glial Derived Neurotrophic Factor), whose role is to improve the health and function of degenerating dopamine- secreting neurons and to keep them alive and functioning normally. Learn more NET-PD LS-1 Creatine in Parkinson's Disease, Recruiting 1,720 Participants - NET-PD is a large NIH-sponsored effort to find drugs that slow the progression of PD. Symptoms of PD may include tremor, rigidity or stiffness of the limbs and trunk, slowness of movement, and impaired balance and coordination. These problems occur because as PD worsens, some of the brain cells that control body movement die. This study will determine if creatine, an investigational drug, is able to slow the progression of PD. Learn moreView All Clinical Trials Ceregene Presents Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients Ceregene, Inc., a biopharmaceutical company, today presented long term follow-up data from a Phase 1 clinical trial of CERE-120, a gene therapy product in development for the treatment of Parkinson's disease, demonstrating a 36 percent reduction in Parkinson's symptoms at 12 months after administration. CERE-120 was also shown to be well tolerated in this study.Read more FDA Takes Pergolide Off US Market The FDA has announced that the companies that manufacture and distribute pergolide have agreed to withdraw this drug from the market due to the potential for heart valve damage. Pergolide is a member of a class of drugs known as dopamine agonists and is used with levodopa and carbidopa to manage the signs and symptoms (tremors and slowness of movement) of PD.Read more The 2007 Unity Walk To Be Held on April 28th The Parkinson's Unity Walk is the largest grassroots fundraiser for Parkinson's research in the community. Since 1994, families, friends, caregivers, and major Parkinson's foundations have gathered once a year to unify with the common goal of finding a cure for Parkinson's disease.Read more Help Inform Others About Clinical Trials! Do you find the information in this email bulletin and on PDtrials.org to be a helpful resource? If so, won't you take a moment and send this email bulletin to others? Just click on the "Send" button located on the top left of this page and enter the email addresses of friends, family, support group members, and others who you think would like to learn more about clinical studies. Copyright (c) 2007 PDtrials. All rights reserved. Forward email ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn